Quote of the Day

"I think the unintended consequence of more stringent FDA quality reviews that were put in place three to five years ago was reduced competition, whether through consolidation or firms just going out of business. Until there's additional competition in the space and the products that are under review are approved, we don't see [the generic drug inflation rate] coming down; we see it potentially going up a little from where it is today until increased product is put on the market."



— Bryan Birch, chairman, president and CEO of Truveris, a health information technology company that provides audit services and issues the monthly Truveris National Drug Index, in an interview with AIS's Drug Benefit News.